CA2948178A1 - Anti-viral compounds, pharmaceutical compositions, and methods of use thereof - Google Patents

Anti-viral compounds, pharmaceutical compositions, and methods of use thereof Download PDF

Info

Publication number
CA2948178A1
CA2948178A1 CA2948178A CA2948178A CA2948178A1 CA 2948178 A1 CA2948178 A1 CA 2948178A1 CA 2948178 A CA2948178 A CA 2948178A CA 2948178 A CA2948178 A CA 2948178A CA 2948178 A1 CA2948178 A1 CA 2948178A1
Authority
CA
Canada
Prior art keywords
virus
compound
optionally substituted
formula
independently
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2948178A
Other languages
English (en)
French (fr)
Inventor
Shawn P. Iadonato
Kristin M. Bedard
Kerry W. Fowler
Ikenna MADU
Shari KAISER
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kineta Inc
Original Assignee
Kineta Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kineta Inc filed Critical Kineta Inc
Publication of CA2948178A1 publication Critical patent/CA2948178A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D277/62—Benzothiazoles
    • C07D277/68—Benzothiazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D277/82—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Pulmonology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
CA2948178A 2014-05-09 2015-05-08 Anti-viral compounds, pharmaceutical compositions, and methods of use thereof Abandoned CA2948178A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201461991418P 2014-05-09 2014-05-09
US61/991,418 2014-05-09
US201562177900P 2015-03-25 2015-03-25
US62/177,900 2015-03-25
PCT/US2015/030014 WO2015172099A1 (en) 2014-05-09 2015-05-08 Anti-viral compounds, pharmaceutical compositions, and methods of use thereof

Publications (1)

Publication Number Publication Date
CA2948178A1 true CA2948178A1 (en) 2015-11-12

Family

ID=54393071

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2948178A Abandoned CA2948178A1 (en) 2014-05-09 2015-05-08 Anti-viral compounds, pharmaceutical compositions, and methods of use thereof

Country Status (9)

Country Link
US (3) US9884876B2 (OSRAM)
EP (1) EP3139920A4 (OSRAM)
JP (1) JP6419313B2 (OSRAM)
CN (1) CN106456615B (OSRAM)
AU (3) AU2015255714B2 (OSRAM)
CA (1) CA2948178A1 (OSRAM)
MX (2) MX2016014642A (OSRAM)
TW (1) TW201623265A (OSRAM)
WO (1) WO2015172099A1 (OSRAM)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2018252193B2 (en) 2017-04-14 2024-12-12 Tallac Therapeutics, Inc. Immunomodulating polynucleotides, antibody conjugates thereof, and methods of their use
CA3051422A1 (en) * 2018-08-09 2020-02-09 Kineta, Inc. Activators of the retinoic acid inducible gene "rig-i" pathway and methods of use thereof
TW202035426A (zh) * 2018-08-17 2020-10-01 美商奇尼塔公司 視黃酸誘導基因"rig-i"途徑之活化劑及其使用方法
JP2022506351A (ja) * 2018-11-02 2022-01-17 アイクリス ゲゼルシャフト ミット ベシュレンクテル ハフツング ウント コンパニー コマンディトゲゼルシャフト Ｂ型肝炎ウイルス（ｈｂｖ）に対して活性を有する新規ウレア６，７－ジヒドロ－４ｈ－チアゾロ［５，４－ｃ］ピリジン
AU2020289560A1 (en) * 2019-06-05 2021-12-23 Emory University Peptidomimetics for the treatment of coronavirus and picornavirus infections
WO2021007283A1 (en) * 2019-07-09 2021-01-14 Regents Of The University Of Minnesota Potentiation of antiviral nucleobases as rna virus therapy
EP4037706A4 (en) * 2019-10-02 2023-09-13 University of Washington Compositions and methods for treatment of hepatitis b virus infection
US11920136B2 (en) 2020-02-28 2024-03-05 Tallac Therapeutics, Inc. Transglutaminase-mediated conjugation
WO2021198980A1 (en) 2020-04-04 2021-10-07 Pfizer Inc. Methods of treating coronavirus disease 2019
WO2021205290A1 (en) 2020-04-05 2021-10-14 Pfizer Inc. Compounds and method of treating covid-19
CN114641485A (zh) 2020-04-05 2022-06-17 辉瑞大药厂 用于治疗covid-19的化合物和方法
WO2021205296A1 (en) 2020-04-05 2021-10-14 Pfizer Inc. Method of treating covid-19
JP2023524271A (ja) 2020-05-08 2023-06-09 ボルト バイオセラピューティクス、インコーポレーテッド エラスターゼ－基質ペプチドリンカーイムノコンジュゲート、及びそれらの使用
CA3178994A1 (en) 2020-05-19 2021-11-25 Iyassu Sebhat Ampk activators
CN113831301B (zh) * 2020-06-08 2023-06-06 沈阳药科大学 苯并噻唑类衍生物及其用途
JP2023531726A (ja) 2020-06-26 2023-07-25 キャリーオペ，インク． Ａｍｐｋアクチベーター
US20230339930A1 (en) 2020-07-11 2023-10-26 Pfizer Inc. Antiviral Heteroaryl Ketone Derivatives
US11351149B2 (en) 2020-09-03 2022-06-07 Pfizer Inc. Nitrile-containing antiviral compounds
EP4228631B1 (en) * 2020-10-15 2024-08-21 Baden-Württemberg Stiftung gGmbH Flavi-block: a pan-flavivirus inhibitor
CN116897155A (zh) * 2021-02-24 2023-10-17 豪夫迈·罗氏有限公司 用于治疗和预防乙型肝炎病毒感染的苯并噻唑基双环[1.1.1]戊烷衍生物
CN117460738A (zh) * 2021-03-24 2024-01-26 阿纳韦克斯生命科学公司 冠状病毒感染的预防和治疗
WO2022208262A1 (en) 2021-03-30 2022-10-06 Pfizer Inc. Ether-linked antiviral compounds
TWI869780B (zh) 2022-03-02 2025-01-11 美商輝瑞大藥廠 用於篩檢人類個體之呼吸疾病、監測人類個體之呼吸病況以及提供決策支援之方法及電腦化系統
WO2024149990A1 (en) 2023-01-10 2024-07-18 Oxford University Innovation Limited Nirmatrelvir analogs as 3c like protease inhibitors for treating viral infections
WO2024252327A1 (en) 2023-06-09 2024-12-12 Pfizer Inc. Solid forms of n-(methoxycarbonyl)-3-methyl-l-valyl-(4 r)- n-{(1 s)-1-cyano-2-[(3 s)-2-oxopyrrolidin-3-yl]ethyl}-4-(trifluoromethyl)-l-prolinamide and solvates thereof
WO2025037206A1 (en) 2023-08-11 2025-02-20 Pfizer Inc. Deuterated antiviral compounds
WO2025040743A1 (en) 2023-08-22 2025-02-27 Univerza V Ljubljani Conjugated tlr7 and rig-i agonists
WO2025191272A1 (en) 2024-03-13 2025-09-18 Storm Therapeutics Ltd Inhibitory compounds
CN119707862B (zh) * 2025-02-24 2025-06-27 北京悦康科创医药科技股份有限公司 基于RLRs受体激动剂的疫苗佐剂脂质化合物、包含其的组合物及用途

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1024316A (en) * 1911-07-29 1912-04-23 Singer Mfg Co Strip folding and guiding attachment for sewing-machines.
JPS53129036A (en) * 1977-04-18 1978-11-10 Fuji Photo Film Co Ltd Color photographic material
JPH0780355B2 (ja) * 1987-01-22 1995-08-30 富士写真フイルム株式会社 光学的情報記録媒体
GB9923710D0 (en) 1999-10-08 1999-12-08 Proteus Molecular Design Chemical compounds
WO2004078115A2 (en) * 2003-02-28 2004-09-16 Viropharma, Incorporated Benzothiazole compounds, compositions and methods for treatment and prophylaxis of rotavirus infections and associated diseases
EP1680431A1 (en) * 2003-10-17 2006-07-19 Rigel Pharmaceuticals, Inc. Benzothiazole and thiazole'5,5-b!pyridine compositions and their use as ubiquitin ligase inhibitors
MX2010005649A (es) * 2007-11-21 2010-08-18 Abbott Lab Compuestos novedosos como ligandos del receptor canabinoide y sus usos.
US8895596B2 (en) * 2010-02-25 2014-11-25 Merck Sharp & Dohme Corp Cyclic benzimidazole derivatives useful as anti-diabetic agents
WO2012155352A1 (en) 2011-05-19 2012-11-22 Eli Lilly And Company Dihydroisoxazole compounds, parasiticidal uses and formulations thereof
AP2014007595A0 (en) * 2011-09-30 2014-04-30 Kineta Inc Anti-viral compounds
US9073946B2 (en) * 2013-01-15 2015-07-07 Kineta, Inc. Anti-viral compounds
CN103193770B (zh) * 2013-03-20 2015-10-28 中国人民解放军第二军医大学 取代苯并噻唑类抗真菌化合物及其制备方法与应用

Also Published As

Publication number Publication date
MX2020005187A (es) 2020-08-20
US9884876B2 (en) 2018-02-06
CN106456615A (zh) 2017-02-22
JP6419313B2 (ja) 2018-11-07
EP3139920A1 (en) 2017-03-15
WO2015172099A1 (en) 2015-11-12
MX2016014642A (es) 2017-05-25
US20200270274A1 (en) 2020-08-27
CN106456615B (zh) 2020-10-27
AU2020201815A1 (en) 2020-04-02
JP2017515901A (ja) 2017-06-15
US20190002477A1 (en) 2019-01-03
AU2015255714B2 (en) 2019-12-12
EP3139920A4 (en) 2017-11-01
US20170057978A1 (en) 2017-03-02
AU2020204324A1 (en) 2020-07-16
TW201623265A (zh) 2016-07-01
AU2015255714A1 (en) 2016-10-20

Similar Documents

Publication Publication Date Title
US20200270274A1 (en) Anti-viral compounds, pharmaceutical compositions, and methods of use thereof
US20160102099A1 (en) Anti-viral compounds
US20160122312A1 (en) Anti-viral compounds, pharmaceutical compositions and methods of use thereof
AU2017254812B2 (en) Anti-viral compounds
WO2016073947A1 (en) Anti-viral compounds, pharmaceutical compositions, and methods of use thereof
US20150342932A1 (en) Anti-viral compounds
WO2016057518A1 (en) Anti-viral compounds, pharmaceutical compositions, and methods of use thereof
OA19256A (en) Anti-Viral Compounds.
HK1199029B (en) Anti-viral compounds
NZ622636B2 (en) Substituted benzothiazole compounds and their use in the treatment of viral infections

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20200427

FZDE Discontinued

Effective date: 20220913

FZDE Discontinued

Effective date: 20220913